SCHEMBL16468258

SCHEMBL16468258

COc1ccc(C(CN(Cc2cccc(N)c2)C(=O)O)C(C)(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
PTGES O14684 3/20 0.43
TSHR P16473 3/20 0.42
ALDH1A1 P00352 4/20 0.42
NPSR1 Q6W5P4 3/20 0.42
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HSD17B2 P37059 1/20 0.40
HTT P42858 2/20 0.40
NR1H3 Q13133 2/20 0.40
ALOX12 P18054 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SLC2A1 P11166 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16468308 0.92 AOC3 (0.43) MEN1KMT2APTGESTSHRALDH1A1
SCHEMBL16467951 0.90 OPRK1 (0.40) MEN1KMT2APTGESL3MBTL1LMNA
SCHEMBL16468157 0.89 MEN1 (0.53) MEN1KMT2APTGESTSHRALDH1A1
SCHEMBL16468485 0.86 PTGES (0.42) MEN1KMT2APTGESTSHRALDH1A1
SCHEMBL16468252 0.84 PTGES (0.44) MEN1KMT2APTGESNPSR1HSD17B2
SCHEMBL16468155 0.83 PTGES (0.38) KMT2APTGESALDH1A1NPC1RAB9A
SCHEMBL16468270 0.83 OPRK1 (0.39) PTGESHSD17B2LMNA
SCHEMBL16468455 0.83 PTGES (0.41) PTGESTSHRNPSR1HTTSLC2A1
SCHEMBL16468139 0.82 PTGES (0.43) MEN1KMT2APTGESTSHRALDH1A1
SCHEMBL16467940 0.79 CASR (0.43) MEN1KMT2APTGESALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051257-A1 SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES ADAMED SP. ZO.O (PL) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051257-A1 SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES AQP4, BCL6, STS MEN1 2136/4885KMT2A 896/4885PTGES 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.